The childhood cancer neuroblastoma is associated with poor prognosis. To address this, researchers developed a novel technology that promises to deliver drugs within the tumour.
Neuroblastoma is an aggressive solid neuroendocrine tumour that emerges early on in childhood. It has a poor survival rate and accounts for 15 % of cancer-related deaths in children under the age of 15. Such tumours are often impenetrable to chemotherapy agents and as a result resistant to conventional treatments.
Further details: Advancing neuroblastoma therapy